Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents
Article
[키워드] acute respiratory syndrome
Administered
adolescents
Adverse
adverse event
antibody
Antibody titer
Antibody titers
Breakthrough infection
children
clinical effectiveness
conducted
coronavirus
defined
diagnosed
disease
domain
dose
enrolled
evaluated
event
Factor
FIVE
immunogenic
immunogenicity
immunosuppressants
immunosuppressive
immunosuppressive agent
Immunosuppressive agents
Infection
interquartile range
median
median age
Messenger RNA
mRNA
mRNA vaccine
non-recipient
non-specific
occurred
Patient
patients
postvaccination
Prospective Study
recipient
recipients
rejection
SARS-CoV-2
SARS-CoV-2 mRNA vaccine
SARS-CoV-2 spike
SARS-CoV-2 spike protein
SARS-CoV-2 vaccine
significantly lower
solid organ transplant
Solid organ transplant recipients
SOT
titer
vaccination
Vaccine
Vaccine failure
was measured
were measured
[DOI] 10.1111/ped.15331 PMC 바로가기
[DOI] 10.1111/ped.15331 PMC 바로가기